×
0 0 0.102173913043478 0.102173913043478 0.521739130434783 0.517173913043478 0.521739130434783 0.597826086956522
Stockreport

Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder

SAGE THERAPEUTICS (SAGE)  More Company Research Source: Business Wire
Last sage therapeutics earnings: 2/22 06:30 am Check Earnings Report
PDF – SAGE-217 met primary endpoint and provided rapid, profound and durable effects through 2-week treatment period and additional 4-week follow-up – – Well-tolerated and demonstrated highly statistically significant mean reduction in the HAM-D score compared to placebo at 15 days (p – All secondary endpoints were consistent with primary endpoints at Day 15, including remission in 64% of SAGE-217 patients versus 23% of placebo patients (p=0.0005) – – Data support further development of SAGE-217 for MDD and related disorders – – Conference call scheduled today at 8:00 A.M. ET – CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced positive top-line results from the Phase 2, double-blind, placebo-controlle [Read more]

IMPACT SNAPSHOT EVENT TIME: SAGE
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS